Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 30, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Appoints Kathie M. Bishop, Ph.D., as Chief Scientific Officer

SAN DIEGO, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
November 22, 2016 16:05 ET | Source: Otonomy, Inc.

Otonomy to Present at Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
November 03, 2016 16:13 ET | Source: Otonomy, Inc.

Otonomy Reports Third Quarter 2016 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
November 02, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Assignment of J Code for OTIPRIO®

SAN DIEGO, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
October 27, 2016 16:05 ET | Source: Otonomy, Inc.

Otonomy to Report Third Quarter 2016 Financial Results and Provide Corporate Update

SAN DIEGO, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
October 07, 2016 08:00 ET | Source: Otonomy, Inc.

Otonomy Holds Investor and Analyst Day and Provides Corporate Update

SAN DIEGO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
October 04, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Successfully Completes Phase 2 Clinical Trial of OTIPRIO® in Pediatric Patients with Acute Otitis Media with Tympanostomy Tubes

SAN DIEGO, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
September 29, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy to Host Investor and Analyst Day on October 7, 2016

SAN DIEGO, Sept. 29, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
September 15, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes

SAN DIEGO, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
September 13, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting

SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...